---
document_datetime: 2023-09-21 19:33:12
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/eperzan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: eperzan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.2331745
conversion_datetime: 2025-12-14 13:55:52.403542
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Eperzan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                          |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10175 /201703  | Periodic Safety Update EU Single assessment - albiglutide                                                                                                                                                                                                             | 28/09/2017                          | n/a                                            |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |
| II/0031              | Update of section 4.8 of the SmPC in order to include angioedema under the description of 'Allergic reactions'. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder took the opportunity to implement minor editorial product | 14/09/2017                          |                                                | SmPC and PL                      | Signs of severe allergic reactions include raised and itchy rashes and swelling (sometimes of the face, mouth or throat, causing difficulty in breathing). Patients should seek medical help immediately if they observe these symptoms and stop taking Eperzan. |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | amendments throughout the Product Information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                  |                    |           |             | authorised                                                                                                                                                                                                                                                                                                                                         |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0033             | Update of the Package Leaflet in order to amend the layout and content of the Instructions for Use (IFU). In addition, the RMP version 8 has also been submitted to implement additional pharmacovigilance and risk minimisation activities addressing the safety concern of 'medication errors/device issue potentially leading to lack of efficacy or inadequate diabetes control' C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 01/09/2017         | no longer | PL          | The Instructions for Use (IFU) were re-designed to address the issue of non-compliance with the instructions, which constitutes the largest proportion of medication errors. Results of the revised IFU user testing demonstrated that patients could administer Eperzan successfully and the error/unsuccessful administration rate was very low. |
| IAIN/0037           | data C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                               | 10/08/2017 product |           | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                    |
| IA/0035             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                     | 14/07/2017         |           | SmPC        |                                                                                                                                                                                                                                                                                                                                                    |
| II/0032             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority Medicinal                                                                                                                                                                                                                                                                                                                                           | 05/05/2017         | n/a       |             |                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10175 /201609 | Periodic Safety Update EU Single assessment - albiglutide                                                                                                                                                                                                                                                                                                                                                                                                                                         | 06/04/2017         | n/a       |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0028/G   | This was an application for a group of variations. II: C.I.11.b - Submission of a revised RMP in order to introduce medication errors as a new important potential risk II: C.I.11.b - Update of the RMP to add a new category 3 study as an additional pharmacovigilance activity - Study 204879: A Randomized, Open-label, Active-Controlled, Parallel-Group, Exploratory Study on the Effects of Repeated Doses of Albiglutide compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Subjects with Type 2 Diabetes Mellitus II: C.I.11.b - Update of the RMP to add a new category 3 study as an additional pharmacovigilance activity - Study 201840 - An Exploratory Randomized, 2-Part, Single-blind, 2-Period Crossover Study Comparing the Effect of Albiglutide with Exenatide on Regional Brain Activity Related to Nausea in Healthy Volunteers II: C.I.11.b - Update of the RMP to add a new category 3 study as an additional pharmacovigilance activity - Cross-sectional survey to assess the effectiveness of the proposed additional educational materials using Patient Connect C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required Medicinal product   | 23/02/2017   | n/a no longer   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH   | no longer authorised   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| II/0027/G | where significant assessment is required This was an application for a group of variations. Submission of the final study reports for non-clinical toxicity studies: 2015N232567 - Investigation of blood brain barrier penetration of albiglutide in mice and 2016N269355 - Subcutaneous juvenile toxicity study in mice. In addition, the MAH submitted a literature review on glucagon like peptide 1 receptor (GLP-1R) distribution patterns in thyroid and pancreas tissue and results of two additional juvenile toxicology dose response studies as part of this group of Medicinal product                                                                                                                                                                                                                                                    | 15/12/2016             |

<div style=\"page-break-after: always\"></div>

|                     | variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                           |            |               |                                  | authorised                                                                                                                                                                             |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10175 /201603 | Periodic Safety Update EU Single assessment - albiglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 13/10/2016 | 08/12/2016    | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10175/201603.                                             |
| IB/0026             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                      | 31/08/2016 | n/a           | longer                           |                                                                                                                                                                                        |
| II/0022             | Update of section 6.6 of the SmPC for increased clarity in order to address the newly identified potential risk of medication errors. The Package Leaflet (including Instructions for Use) is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to combine SmPCs of authorised strengths and bring the Annex II and Annex IIIA in line with the latest QRD template version 10. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data Medicinal product | 21/07/2016 | 08/12/2016 no | SmPC, Annex II, Labelling and PL | Patient should read the full Instructions for Use (IFU) including the Questions and Answers before starting the therapy and refer back to the IFU each time before injecting the dose. |

<div style=\"page-break-after: always\"></div>

| IB/0025   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 20/06/2016   | n/a           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|
| II/0023/G | This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the Medicinal product | 26/05/2016   | n/a no longer |

<div style=\"page-break-after: always\"></div>

|                     | obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation   |            |            |             | authorised                        |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| II/0020             | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                     | 19/05/2016 | n/a        | longer      |                                   |
| II/0019             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol product                                                                                                                         | 28/04/2016 | n/a no     |             |                                   |
| PSUSA/10175 /201509 | Periodic Safety Update EU Single assessment - albiglutide                                                                                                                                                                                                                                                                                                                                  | 14/04/2016 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0021             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol Medicinal                                                                                                                                                                                              | 31/03/2016 | 08/12/2016 | SmPC and PL |                                   |
| IB/0016             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                                                                                        | 10/12/2015 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

|                     | Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                 |            |            |        | authorised                        |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------|-----------------------------------|
| N/0018              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                       | 08/12/2015 | 08/12/2016 | PL     |                                   |
| IA/0015             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                       | 02/12/2015 | n/a        | longer |                                   |
| PSUSA/10175 /201503 | Periodic Safety Update EU Single assessment - albiglutide                                                                                                                                                                                                                                                                                              | 08/10/2015 | n/a        |        | PRAC Recommendation - maintenance |
| II/0013/G           | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority product | 24/09/2015 | n/a no     |        |                                   |
| II/0012             | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                 | 09/07/2015 | n/a        |        | PRAC Recommendation - maintenance |
| PSUSA/10175 /201409 | Periodic Safety Update EU Single assessment - albiglutide                                                                                                                                                                                                                                                                                              | 10/04/2015 | n/a        |        |                                   |
| IB/0011             | To extend the albiglutide active substance shelf life from 24 months to 36 months at the currently registered storage condition 'Store at ≤ -35°C, Medicinal                                                                                                                                                                                           | 23/12/2014 | n/a        |        |                                   |

<div style=\"page-break-after: always\"></div>

|         | protected from light.' B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                 |            |               |                               | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0008 | Update of sections 4.8 of the Summary of Product Characteristics (SmPC) with information on hypersensitivity and allergic reactions. The Package Leaflet (PL) is updated accordingly. In addition, minor editorial changes are made to sections 5.1 and 6.6 of the SmPC, the Annex IIIA and the PL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data product | 18/12/2014 | 19/06/2015 no | SmPC, Labelling and PL longer | The MAH conducted an updated review of data from 7 clinical trials included in the safety analysis of the initial marketing authorisation using a MedDRA SMQ version 16.1 for hypersensitivity reactions. The overall incidence of any serious hypersensitivity reaction identified with this query was similar in the albiglutide group compared to the all comparators group (0.4%). Furthermore, the overall incidence of any event of hypersensitivity reactions also appeared to be similar between the groups; 17.1% vs. 14.9% for albiglutide vs. the all comparators group However, a non-serious hypersensitivity event was consistent with a possible drug-related systemic hypersensitivity reaction. Consequently, section 4.8 of the SmPC was updated to indicate that possible hypersensitivity reactions (e.g. pruritus, erythema), including a case with generalized pruritus and rash with dyspnoea, have been reported in clinical trials with albiglutide. |
| II/0006 | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                         | 25/09/2014 | n/a           |                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0005 | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance Medicinal                                                                                                                                                                                                                                                        | 25/09/2014 | n/a           |                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                                                                                                                                                                                                                                                                              |            |               |                                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-----------------------------------|
| IB/0004/G | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes | 05/09/2014 | 19/06/2015    | SmPC, Labelling and PL authorised |
| IB/0007   | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                    | 13/08/2014 | n/a           | longer                            |
| IG/0442   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                 | 05/06/2014 | 19/06/2015 no | SmPC, Labelling and PL            |
| IB/0001   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS product                                                                                                                                                                                                                                                                                                                                   | 09/05/2014 | n/a           |                                   |
| IB/0002   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                       | 02/05/2014 | n/a           |                                   |